dMMR
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR | Non-Small Cell Lung Cancer | Cemiplimab | |
| FDA (1) HSE (1) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| EMA (1) FDA (1) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| FDA (1) | dMMR | Any solid tumor | Dostarlimab | |
| EMA (1) FDA (1) | dMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Paclitaxel | |
| FDA (1) | dMMR | Any solid tumor | Pembrolizumab | |
| EMA (1) FDA (1) HSE (2) | dMMR | Colorectal Adenocarcinoma | Pembrolizumab | |
| EMA (4) FDA (2) HSE (2) | dMMR | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| FDA (1) | dMMR | Colorectal Adenocarcinoma | Nivolumab | |
| EMA (1) | dMMR | Endometrial Carcinoma | Pembrolizumab | |
| EMA (1) | dMMR | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| EMA (1) | dMMR | Gastrointestinal Stromal Tumor | Pembrolizumab | |
| EMA (1) | dMMR | Cholangiocarcinoma | Pembrolizumab |